The Q3 result was announced after market hours on Monday, 10 February 2014.

Meanwhile, the S&P BSE Sensex was up 66.20 points or 0.33% at 20,400.47.

On BSE, so far 80,000 shares were traded in the counter as against average daily volume of 4,596 shares in the past one quarter.

The stock hit a high of Rs 846.80 and a low of Rs 757.25 so far during the day. The stock had hit a 52-week high of Rs 1,308.20 on 12 February 2013. The stock had hit a 52-week low of Rs 595 on 26 March 2013.

The stock had underperformed the market over the past one month till 10 February 2014, sliding 9.15% compared with the Sensex's 2.04% fall. The scrip had also underperformed the market in past one quarter, declining 15.51% as against Sensex's 1.61% fall.

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

Astrazeneca Pharma India's net sales rose 13.3% to Rs 118.88 crore in Q3 December 2013 over Q3 December 2012.

AstraZeneca Pharma India is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.